Develops drugs for bipolar disorder, schizophrenia, and multiple sclerosis.
Jun 2026Revenue $216M/yrExpenses $401M/yr
No trendCash runway ≈ 5 months from Jun 2026
Figures by year
When will Vanda Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $216M and expenses $401M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $216M | $367M | −$151M |
| Dec 2024 | $199M | $239M | −$40.7M |
| Dec 2023 | $193M | $207M | −$14.0M |
| Dec 2022 | $254M | $248M | $6.33M |
| Dec 2021 | $269M | $227M | $42.2M |
| Dec 2020 | $248M | $221M | $27.2M |
| Dec 2019 | $227M | $204M | $22.8M |
| Dec 2018 | $193M | $171M | $21.7M |
| Dec 2017 | $165M | $182M | −$16.9M |
| Dec 2016 | $146M | $165M | −$18.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.